HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy

BACKGROUND: Virological failure (VF) to boosted PIs with a high genetic barrier is not usually linked to the development of resistance-associated mutations in the protease gene. METHODS: From a cohort of 520 HIV-infected subjects treated with lopinavir/ritonavir or darunavir/ritonavir monotherapy, w...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Antimicrob Chemother
Autors principals: Blanch-Lombarte, Oscar, Santos, José R, Peña, Ruth, Jiménez-Moyano, Esther, Clotet, Bonaventura, Paredes, Roger, Prado, Julia G
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7443716/
https://ncbi.nlm.nih.gov/pubmed/32556165
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkaa228
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars